Our International Value Equity strategy delivered a 35.5% return, producing attractive absolute results and outperforming ...
Q4 2025 Earnings Call February 5, 2026 9:30 AM ESTCompany ParticipantsAshley Serrao - MD, Head of Treasury, FP&A ...
The primary finding from the clinical trials for the COPD biologics is reduced annual exacerbations by 30% (BOREAS trial) and 34% (NOTUS trial). In the BOREAS trial, in addition to reduced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results